Literature DB >> 32801018

Bone health in cancer: ESMO Clinical Practice Guidelines.

R Coleman1, P Hadji2, J-J Body3, D Santini4, E Chow5, E Terpos6, S Oudard7, Ø Bruland8, P Flamen9, A Kurth10, C Van Poznak11, M Aapro12, K Jordan13.   

Abstract

Entities:  

Keywords:  Clinical Practice Guidelines; bone metastases; bone-targeted agents; cancer treatment-induced bone loss; diagnosis; follow-up; treatment

Mesh：

Year:  2020        PMID： 32801018     DOI： 10.1016/j.annonc.2020.07.019

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  55 in total

1.  Optimal duration of adjuvant bisphosphonate treatment for high-risk early breast cancer: Results from a SUCCESS trial.

Authors:  Mingbei Lu; Beibei Ren; Lingyan Rao
Journal:  Thorac Cancer       Date:  2022-01-02       Impact factor: 3.500

2.  Incidence of Post-denosumab Rebound Hypercalcaemia in Bony-Metastatic Breast Cancer.

Authors:  Ray Wang; Subanki Rajanayagam; Jennifer Ngan; Debra A Renouf
Journal:  Calcif Tissue Int       Date:  2022-07-09       Impact factor: 4.000

3.  Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points.

Authors:  Vittorio Fusco; Maura Rossi; Antonella Fasciolo; Alessio Gambino; Serena Palmeri
Journal:  Support Care Cancer       Date:  2022-07-27       Impact factor: 3.359

Review 4.  AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.

Authors:  Nina Ditsch; Achim Wöcke; Michael Untch; Christian Jackisch; Ute-Susann Albert; Maggie Banys-Paluchowski; Ingo Bauerfeind; Jens-Uwe Blohmer; Wilfried Budach; Peter Dall; Eva Maria Fallenberg; Peter A Fasching; Tanja N Fehm; Michael Friedrich; Bernd Gerber; Oleg Gluz; Nadia Harbeck; Jörg Heil; Jens Huober; Hans H Kreipe; David Krug; Thorsten Kühn; Sherko Kümmel; Cornelia Kolberg-Liedtke; Sibylle Loibl; Diana Lüftner; Michael Patrick Lux; Nicolai Maass; Christoph Mundhenke; Ulrike Nitz; Tjoung-Won Park-Simon; Toralf Reimer; Kerstin Rhiem; Achim Rody; Marcus Schmidt; Andreas Schneeweiss; Florian Schütz; Hans-Peter Sinn; Christine Solbach; Erich-Franz Solomayer; Elmar Stickeler; Christoph Thomssen; Isabell Witzel; Volkmar Müller; Wolfgang Janni; Marc Thill
Journal:  Breast Care (Basel)       Date:  2022-05-05       Impact factor: 2.268

5.  Chemoembolization for Symptomatic Metastatic Epidural Spinal Cord Compression Refractory to Re-radiotherapy.

Authors:  Joichi Heianna; Wataru Makino; Masafumi Toguchi; Takeaki Kusada; Tomotaka Iraha; Kazuki Ishikawa; Shota Takehara; Hitoshi Maemoto; Takuro Ariga; Sadayuki Murayama
Journal:  Cardiovasc Intervent Radiol       Date:  2021-08-02       Impact factor: 2.740

Review 6.  Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review.

Authors:  Bethânia Soares Dos Santos; Cláudia Bordignon; Daniela Dornelles Rosa
Journal:  Curr Oncol Rep       Date:  2021-04-14       Impact factor: 5.075

7.  Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences.

Authors:  Stella D'Oronzo; Walter Gregory; Simon Nicholson; Yuen Khong Chong; Janet Brown; Robert Coleman
Journal:  J Bone Oncol       Date:  2021-05-04       Impact factor: 4.072

8.  Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation.

Authors:  Sharon McGee; Mashari AlZahrani; Carol Stober; Terry L Ng; Katherine Cole; Gail Larocque; Arif Awan; Sandeep Sehdev; John Hilton; Lisa Vandermeer; Brian Hutton; Gregory Pond; Deanna Saunders; Mark Clemons
Journal:  J Bone Oncol       Date:  2021-02-19       Impact factor: 4.072

9.  Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations.

Authors:  J E Brown; S L Wood; C Confavreux; M Abe; K Weilbaecher; P Hadji; R W Johnson; J A Rhoades; C M Edwards; P I Croucher; P Juarez; S El Badri; G Ariaspinilla; S D'Oronzo; T A Guise; C Van Poznak
Journal:  J Bone Oncol       Date:  2021-06-11       Impact factor: 4.072

10.  Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases.

Authors:  Domenica Lovero; Stella D'Oronzo; Raffaele Palmirotta; Paola Cafforio; Janet Brown; Steven Wood; Camillo Porta; Eleonora Lauricella; Robert Coleman; Franco Silvestris
Journal:  Br J Cancer       Date:  2021-07-16       Impact factor: 9.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.